CRXM Financials 07/16/2014 18:52:02
Cardium Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 109 59 - 244
Cost of Revenue 69 54 - -
Gross Profit 40 5 - 244
Operating Expenses
Research and Development 2,037 2,581 2,593 2,314
Sales, General and Admin. 4,909 5,718 4,825 4,700
Non-Recurring Items - - - -
Other - - - -
Operating Income (6,906) (8,294) (7,418) (6,770)
Income From Continuing Operations
Add'l Income/Expense Items - 71 294 2,036
Earnings Before Interest and Tax (6,906) (8,223) (7,124) (4,733)
Interest Expense 1 4 6 3
Earnings Before Tax (6,907) (8,227) (7,129) (4,736)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (6,907) (8,227) (7,129) (4,736)
Non Recurring Events
Discontinued Operations (2,007) (96) - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (8,914) (8,323) (7,129) (4,736)
Preferred Stock and Other Adjustments (406) - - -
Net Income Applicable to Common Shareholders (9,320) (8,323) (7,129) (4,736)